View More Recent Stories
-
Evaxion Biotech (EVAX) obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
-
Evaxion Biotech (EVAX) Provides Shareholder Update
-
Evaxion Biotech (EVAX) Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
-
Evaxion Biotech (EVAX) Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
